Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Multiple Myeloma · Multiple Myeloma (MM) · CCCC

C4 Therapeutics

C4 Therapeutics patent portfolio — 24 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
WATERTOWN, MA, USA HQ
2024 Founded
2 Employees
Public company Type
CCCC · NYSE Ticker
Company details
Status
Public
HQ
WATERTOWN, MA, USA
Founded
2024
Employees
2
Programs
4
Drugs
1
Patents
24
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

C4 Therapeutics patents

24 pharmaceutical patents indexed for C4 Therapeutics. 0 expire within 24 months.

C4 Therapeutics has 24 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

24 patents

Patent portfolio

  1. US 12421220

    Bicyclic-substituted glutarimide cereblon binders

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12371442

    Isoindolinone and indazole compounds for the degradation of EGFR

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12227504

    Spirocyclic compounds

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12180225

    N/O-linked degrons and degronimers for protein degradation

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12157735

    Compounds for targeted degradation of BRD9

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12091397

    Dihydroquinolinones for medical treatment

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12076405

    Heterocyclic degronimers for target protein degradation

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12048747

    Substituted piperidine Degronimers for Target Protein degradation

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12049464

    Compounds for targeted degradation of BRD9

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12048748

    Spirocyclic degronimers for target protein degradation

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11992531

    C3-carbon linked glutarimide degronimers for target protein degradation

    Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11802131

    Glutarimides for medical treatment

    Expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11753397

    Cereblon binders for the degradation of ikaros

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11691972

    Compounds for targeted degradation of BRD9

    Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11673902

    Isoindolinone and indazole compounds for the degradation of EGFR

    Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11623929

    Spirocyclic compounds

    Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11584748

    Spirocyclic compounds

    Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11459335

    N/O-linked Degrons and Degronimers for protein degradation

    Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11401256

    Dihydroquinolinones for medical treatment

    Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11185592

    Spirocyclic degronimers for target protein degradation

    Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10905768

    Heterocyclic degronimers for target protein degradation

    Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10849982

    C3-carbon linked glutarimide degronimers for target protein degradation

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10660968

    Spirocyclic degronimers for target protein degradation

    Expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10646575

    Heterocyclic degronimers for target protein degradation

    Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does C4 Therapeutics have?

24 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do C4 Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.